Autolus Therapeutics (NASDAQ:AUTL) Reaches New 1-Year Low – Here’s Why

Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price reached a new 52-week low during trading on Friday . The company traded as low as $2.60 and last traded at $2.65, with a volume of 549381 shares changing hands. The stock had previously closed at $2.69.

Analysts Set New Price Targets

A number of research firms recently commented on AUTL. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the company from $7.00 to $7.60 in a report on Monday, November 18th. Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Thursday, December 5th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $10.40.

Autolus Therapeutics Stock Performance

The company has a 50-day simple moving average of $3.57 and a two-hundred day simple moving average of $3.84. The firm has a market capitalization of $662.56 million, a P/E ratio of -2.06 and a beta of 1.98.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter in the previous year, the firm posted ($0.26) EPS. As a group, research analysts forecast that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Several large investors have recently made changes to their positions in the business. Exchange Traded Concepts LLC lifted its holdings in shares of Autolus Therapeutics by 9.8% during the third quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company’s stock valued at $152,000 after purchasing an additional 3,740 shares during the last quarter. Wealth Effects LLC lifted its holdings in shares of Autolus Therapeutics by 19.5% during the second quarter. Wealth Effects LLC now owns 49,000 shares of the company’s stock valued at $171,000 after purchasing an additional 8,000 shares during the last quarter. Bellevue Group AG lifted its holdings in shares of Autolus Therapeutics by 27.7% during the third quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock valued at $151,000 after purchasing an additional 9,000 shares during the last quarter. State Street Corp lifted its holdings in shares of Autolus Therapeutics by 1.7% during the third quarter. State Street Corp now owns 606,544 shares of the company’s stock valued at $2,202,000 after purchasing an additional 10,401 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new position in Autolus Therapeutics in the 2nd quarter worth approximately $43,000. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.